1) AWS Trainium: it remains a global debate whether Marvell will win part of the Trainium3 business (link). At least our checks suggest that Alchip taped out the Trainium3 design back in February, and the wafers were already out in May. Charlie Chan thinks Alchip has a higher chance to win the 2nm Trainium4, which should be decided this summer. Astera Labs and Alchip just formed a partnership in connectivity chip design (I/O chiplets). We think that may help Alchip compete for next-generation XPU ASIC proje ...

Asia AI Server Global Markets Research EQUITY: TECHNOLOGY Meta's ambition on ASIC AI server Meta's MTIA AI servers could mark a milestone in 2026F AI ASIC is booming; a potential cross over in units from 2H26-2027 In the world of AI servers, nVidia (NVDA US, Not rated) has been dominating 80%+ market "value" so far, vs. ASIC AI servers that have roughly 8-11% in value share (based on Bloomberg consensus estimates). However, if we just compare the number of units for AI ASICs vs. nVidia's AI GPUs (which can ...

[CC may contain inaccuracies] How important is the Strait of Hormuz right now. And even if we don't necessarily see a closure or just disruptions in that region. I mean, massively important, 20% of the world's oil is flowing there and the roughly equivalent amount of the world's gas.What is particularly challenging right now is some of the jamming that's happening on GPS devices and the like, which which is a concern. The Strait of Hormuz is, at the end of the day, the artery through which the world's energ ...

Core Insights - Annexon, Inc. has appointed Dr. Lloyd Clark as senior vice president of ophthalmology strategy and innovation, bringing over 25 years of experience in retina diseases and drug development [1][3] - The investigational therapy ANX007 is the only treatment shown to significantly preserve vision and central retinal photoreceptors in patients with dry age-related macular degeneration (AMD) with geographic atrophy (GA) [2][3] - The Phase 3 ARCHER II trial for ANX007 is expected to complete enrollment by Q3 2025, with topline data anticipated in the second half of 2026 [2][6] Company Overview - Annexon, Inc. focuses on developing novel therapies for neuroinflammatory diseases, targeting the classical complement pathway to prevent tissue damage [7] - The company aims to address significant unmet needs in the treatment of neurodegenerative and ophthalmic diseases, with a pipeline that includes investigational drug candidates for over 8 million patients globally [7] Product Details - ANX007 is designed to block C1q locally in the eye and is currently being evaluated in the pivotal Phase 3 ARCHER II trial, which will enroll approximately 630 patients [2][6] - The primary endpoint of the ARCHER II trial is to prevent a ≥15-letter loss in best corrected visual acuity (BCVA), a well-established functional endpoint for ophthalmology drug approvals [6] Market Context - Dry AMD with GA is a leading cause of blindness affecting over 8 million patients worldwide, with no approved therapies currently available to preserve vision [2][4] - The addition of Dr. Clark to the Annexon team is seen as a strategic move to enhance the company's position in the retina community and improve treatment options for patients with dry AMD [3]

Heat. Heat. [Music] Heat. [Music] Heat. [Applause] [Music] [Applause] [Music] Heat.Heat. Heat. Heat. [Music] [Applause] [Music] [Applause] Heat. Heat.[Music] [Applause] Heat. Heat. [Music] [Applause] [Music] [Applause] Doo doo doo doo doo doo.D [Music] [Music] my love on the moon with you. I think I reaches you in the way. The ocean colors on your face.I'll leave my heart with your air. So let me fly with you. Will you be forever with me.[Music] [Music] your morning eyes. I could stare like watching stars. ...

Core Viewpoint - Marvell Technology (MRVL.US) has seen a significant stock price increase due to positive evaluations from top Wall Street analysts regarding its customized AI ASIC chip activities and potential market announcements [1][3] Group 1: Market Opportunities - Analysts from Evercore ISI predict that the new AI ASIC chip designs could ramp up quickly between 2026 and 2027, indicating strong future demand [1] - Marvell expects each customized AI chip design win to generate billions in lifecycle revenue within 1.5 to 2 years, while each XPU Attach win could contribute hundreds of millions within 2 to 4 years [2] - The total addressable market (TAM) for customized data center chips has been raised to $94 billion, a 26% increase from last year's AI activities [3] Group 2: Financial Projections - Marvell has raised its financial targets, with analysts noting that the potential earnings per share could reach $8 by 2028, exceeding Wall Street estimates by 60% [4] - The company aims to capture at least 20% of the TAM, with over 50% of its data center revenue expected to come from AI ASIC-related demands [3][5] Group 3: Competitive Landscape - Broadcom (AVGO.US) is identified as the long-term beneficiary of Marvell's AI activities, holding a dominant market share of approximately 60% in the AI ASIC sector, while Marvell holds 13% to 15% [6][7] - The AI ASIC market is expected to grow significantly, with major tech companies like Google, Microsoft, and Amazon investing heavily in AI ASIC chips, indicating a shift in market dynamics away from GPU dominance [7]

Force. Eventually, over the next few years, he wrote in a memo to employees that they should figure out, in his words, how to get more done with scrappier teams. That's nice.Joining us now, former Democratic presidential candidate Andrew Yang. It's a daunting future we have. Mr.. Yang, obviously. And you've been I said we I was at a was it a book party that that I attended for you, a book of six years, six years ago, talking about this on the horizon and the need for maybe even back then, universal basic in ...

Core Insights - Aethlon Medical has achieved a significant milestone by treating the second patient with the Hemopurifier in its clinical trial for solid tumors not responding to anti-PD-1 antibodies [1][2] - The trial aims to assess the safety and feasibility of the Hemopurifier, with the first cohort consisting of approximately 18 patients [6] - The Hemopurifier is designed to remove tumor-derived extracellular vesicles (EVs) from the bloodstream, potentially improving responses to anti-PD-1 therapies [5][7] Group 1: Clinical Trial Progress - The second patient was treated on June 11, 2025, at the Royal North Shore Hospital/University of Sydney, following the first patient treated on January 29, 2025 [1][2] - Both patients completed the 4-hour Hemopurifier treatment without device deficiencies or immediate complications, and have finished the 7-day safety follow-up period [2][4] - The Data Safety Monitoring Board (DSMB) will review the safety data after the third patient is enrolled, which is expected to occur soon [3][4] Group 2: Device and Mechanism - The Hemopurifier is an investigational device that utilizes plasma separation and affinity binding to remove enveloped viruses and EVs from circulation [7][8] - Preclinical studies indicate that the Hemopurifier can reduce the number of exosomes in cancer patient plasma, which may enhance the effectiveness of anti-PD-1 therapies [5][6] - The device holds FDA Breakthrough Device designation for treating advanced or metastatic cancer patients who are unresponsive to standard therapies [8] Group 3: Future Directions - The primary endpoint of the trial is to monitor adverse events and significant changes in safety lab tests among treated patients [6] - The study will also explore the number of Hemopurifier treatments required to decrease EV concentrations and whether this improves the immune response against tumor cells [6] - Data on the effects of the Hemopurifier on anti-tumor T cell activity is anticipated approximately three months after the enrollment of the third patient [3]

在指数持续缩量震荡，题材板块高速轮动的内卷大环境中， AI 算力中机构大票却走出了一波 凌厉的连续上涨，相关个股在股价走到高位高位之后，非但没有调整，反而是在今天进一步大 涨， PCB 板块更是掀起涨停潮，沪电股份这种权重股牢牢封死涨停。 今天这样的走势，是什么原因所导致的呢，产业上有什么新的变化？ 昨天晚上， Marvell 举行科技研讨会，对未来业务的预测，到 2028 年数据中心市场将达 940 亿美元，较此前上修了 26% 。其中 AI 定制计算和高性能互联是最关键的增长引擎，年 复合增长率分别高达 53% 和 35% 。 过去一周市场对于 ASIC 的预期已经比较高， Marvell 的会进一步强化市场预期。 对于国内产业链来说，核心的映射方向，就是 PCB 、 CCL 以及光模块。相较于 GPU ， ASIC 对于 PCB 、 CCL 以及光模块的用量都会有明显提升，尤其是 PCB 的用量提升更为明 显。 在 A 股当下的市场环境当中，有相当多资金在厌倦了无穷无尽的轮动行情之后，选择去本身 业绩就相当扎实的 AI 算力里面抱团。 再遇上新的产业变化，提高了未来的业绩预期，走出今天这样的强势行情也就 ...

I NVES TOR PR ESENTATI ON June 2025 Disclaimer Forward Looking Statements This presentation contains "forward-looking statements" for purposes of the safe harbor provisions under the U.S. Private securities litigation reform act of 1995, as amended. These forward-looking statements are generally identified by words such as "anticipate," "believe," continue," "could," "estimate," "expect," "intend," "may," "might," "seem," "seek," "future," "outlook," "model," "target," "goal," "plan," "possible," "potential ...